The following is a summary of the Phibro Animal Health Corporation (PAHC) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Phibro Animal Health Corporation reported Q3 2024 net sales of $263.2 million, representing a 7% increase from the same quarter a year prior.

• The company saw different performance across its segments with net sales in the Animal Health segment increasing by 10%, a meager 2% growth in Mineral Nutrition, while Performance Products experienced a decline.

• Adjusted EBITDA saw an increment of $2.3 million due to improved numbers in the Animal Health and Mineral Nutrition sectors.

• The firm recorded 9% rises in both adjusted net income and adjusted diluted earnings per share (EPS).

• The Animal Health division was the star performer this quarter with double-digit growth in the top line.

Business Progress:

• The company is geared up for integrating new colleagues and products from Phibro following its acquisition of Zoetis' medicated feed additive portfolio.

• The Zoetis acquisition is expected to increase Phibro's product diversity, species offerings, and also bolster its earnings along with facilitating debt repayment.

• Phibro is optimistic about sustained growth in its Animal Health business and improvements in the Mineral Nutrition and Performance Products businesses.

• The company reaffirms its initial guidance concerning net sales, adjusted EBITDA, and adjusted diluted earnings per share.

More details: Phibro Animal Health IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.